Please assess the completion status of the following clinical trial:

Trial Title: Corifollitropin Alfa in Participants Undergoing Repeated Controlled Ovarian Stimulation (COS) Cycles Using a Multiple Dose Gonadatropin Releasing Hormone (GnRH) Antagonist Protocol (Study 38825)(P05714)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Females of couples with an indication for COS and IVF or ICSI;~* \>=18 and \<=39 years of age at the time of signing informed consent;~* Body weight \> 60 kg and body mass index (BMI) \>=18 and \<=29 kg/m\^2;~* Normal menstrual cycle length: 24-35 days;~* Availability of ejaculatory sperm (use of donated and/or cryopreserved sperm is allowed);~* Willing and able to sign informed consent.~Exclusion Criteria:~* History of or any current (treated) endocrine abnormality;~* History of ovarian hyper-response or history of ovarian hyperstimulation syndrome (OHSS);~* History of or current polycystic ovary syndrome (PCOS);~* More than 20 basal antral follicles (size: \<11 mm, both ovaries combined) as measured on USS in the early follicular phase (menstrual cycle day 2-5);~* Less than 2 ovaries or any other ovarian abnormality, including endometrioma \>10 mm (visible on USS);~* Presence of unilateral or bilateral hydrosalpinx (visible on USS);~* More than three unsuccessful COS cycles since the last established ongoing pregnancy (if applicable);~* History of non- or low ovarian response to FSH/human menopausal gonadotrophin (hMG) treatment;~* FSH \> 12 IU/L or luteinizing hormone (LH) \> 12 IU/L as measured by the local laboratory (sample taken during the early follicular phase: menstrual cycle day 2-5);~* Any clinically relevant abnormal laboratory value based on a sample taken during the screening phase, including abnormal cervical smear (Papanicolaou \[PAP\]\>=III, cervical intraepithelial neoplasia \[CIN\]\>=1);~* Contraindications for the use of gonadotropins (e.g. tumors, pregnancy/lactation, undiagnosed vaginal bleeding, hypersensitivity, ovarian cysts) or GnRH antagonists (e.g. hypersensitivity, pregnancy/lactation);~* Recent history of or current epilepsy, human immunodeficiency virus (HIV) infection, thrombophilia, diabetes or cardiovascular, gastro-intestinal, hepatic, renal, or pulmonary disease;~* Abnormal karyotyping of the participant or her partner (if karyotyping is performed);~* History or presence of alcohol or drug abuse within 12 months prior to signing informed consent;~* Previous use of corifollitropin alfa;~* Use of hormonal preparations within 1 month prior to screening;~* Administration of investigational drugs within three months prior to signing informed consent.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 39 Years
- Healthy Volunteers: f

Study Arms:
- Corifollitropin alfa 150 µg (Type: EXPERIMENTAL): Up to 3 COS cycles (also called treatment cycles) were performed, each including the following: A single injection of 150 µg corifollitropin alfa was administered on Day 2 or 3 of the menstrual cycle (Stimulation Day 1). Administration of GnRH antagonist (0.25 mg/day) started on Stimulation Day 5 or 6 and continued through day of administration of recombinant Human Chorion Gonadotropin (\[rec\]hCG) (5,000-10,000 IU/250 µg). Administration of (rec)hCG occurred when 3 follicles ≥17 mm were observed on ultrasound scan (USS). Daily dosing with Follicle Stimulating Hormone (FSH) (not to exceed 225 IU/day) began on Stimulation Day 8 and continued up to day of (rec)hCG administration. Progesterone for luteal phase support was administered starting on the day of oocyte pick-up (34-36 hours after \[rec\]hCG) and continued for approximately 6 weeks. After COS cycles 1 and 2, Frozen-Thawed Embryo Transfer cycles (up to 3 after each COS cycle) could occur.

Based on this trial design, predict the completion outcome and termination type (if applicable).